Abstract
The metabolism of delavirdine was examined using liver microsomes from several species with the aim of comparing metabolite formation among species and characterizing the enzymes responsible for delavirdine metabolism. Incubation of 10 μM [14C]delavirdine with either an S9 fraction from human jejunum or liver microsomes from rat, human, dog, or monkey followed by high pressure liquid chromatography analysis showed qualitatively similar metabolite profiles among species with the formation of three significant metabolites. The major metabolite was desalkyl delavirdine; however, the identity of MET-7 and MET-7a (defined by high pressure liquid chromatography elution) could not be unambiguously established, but they seem to be related pyridine hydroxy metabolites, most likely derived from 6′-hydroxylation of the pyridine ring. The apparent KM for delavirdine desalkylation activity ranged from 4.4 to 12.6 μM for human, rat, monkey, and dog microsomes, whereas Vmaxranged from 0.07 to 0.60 nmol/min/mg protein, resulting in a wide range of intrinsic clearance (6–135 μL/min/mg protein). Delavirdine desalkylation by microsomes pooled from several human livers was characterized by a KM of 6.8 ± 0.8 μM and Vmax of 0.44 ± 0.01 nmol/min/mg. Delavirdine desalkylation among 23 human liver microsomal samples showed a meaningful correlation (r = 0.96) only with testosterone 6β-hydroxylation, an indicator of CYP3A activity. Among ten human microsomal samples selected for uniform distribution of CYP3A activity, formation of MET-7 was strongly correlated with CYP3A activity (r = 0.95) and with delavirdine desalkylation (r = 0.98). Delavirdine desalkylation was catalyzed by cDNA-expressed CYP2D6 (KM 10.9 ± 0.8 μM) and CYP3A4 (KM 5.4 ± 1.4 μM); however, only CYP3A4 catalyzed formation of MET-7 and MET-7a. Quinidine inhibited human liver microsomal delavirdine desalkylation by about 20%, indicating a minor role of CYP2D6. These findings suggest the potential for clinical interaction with coadministered drugs that are metabolized by or influence the activity of CYP3A or CYP2D6.
Footnotes
-
Send reprint requests to: Richard L. Voorman, Ph.D., Drug Metabolism Research, Bldg. 300-3, Pharmacia and Upjohn, Kalamazoo, MI 49007.
-
↵1 Present address: Department of Drug Metabolism, Pfizer Central Research, Sandwich, Kent, UK.
-
This work was presented in part at the 9th International Conference on Cytochrome P450, Zurich, Switzerland, 1995.
- Abbreviations used are::
- HIV-1
- human immunodeficiency virus type-1
- ESI
- electrospray ionization
- LC
- liquid chromatography
- MS
- mass spectrometry
- TAO
- troleandomycin
- Received December 4, 1997.
- Accepted March 4, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
